Benefits of the intermittent use of 6-mercaptopurine and methotrexate in maintenance treatment for low-risk acute lymphoblastic leukemia in children: Randomized trial from the Brazilian childhood cooperative group - Protocol ALL-99

Journal of Clinical Oncology

Volumn 28, Issue 11, 2010, Pages 1911-1918

  Brandalise, Silvia R ^a   Pinheiro, Vitória R ^a   Aguiar, Simone S ^a   Matsuda, Eduardo I ^a   Otubo, Rosemary ^a   Yunes, José A ^a   Pereira, Waldir V ^a   Carvalho, Eny G ^a   Cristofani, Lilian M ^a   Souza, Marcelo S ^a   Lee, Maria L ^a   Dobbin, Jane A ^a   Pombo de Oliveira, Maria S ^a   Lopes, Luiz F ^a   Melnikoff, Katharina N T ^a   Brunetto, Algemir L ^a   Tone, Luiz G ^a   Scrideli, Carlos A ^a   Morais, Vera L L ^a   Viana, Marcos B ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ASPARAGINASE; CYCLOPHOSPHAMIDE; CYTARABINE; DAUNORUBICIN; DEXAMETHASONE; DOXORUBICIN; FOLINIC ACID; HYDROCORTISONE; MERCAPTOPURINE; MESNA; METHOTREXATE; TIOGUANINE; VINCRISTINE; ANTINEOPLASTIC AGENT;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; ARTICLE; BLOOD TOXICITY; CANCER RISK; CANCER SURVIVAL; CHILD; CHILDHOOD LEUKEMIA; DRUG FATALITY; FEMALE; HUMAN; INFANT; LIVER DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NEPHROTOXICITY; PRESCHOOL CHILD; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; BRAZIL; CANCER STAGING; GENETICS; PATHOLOGY; PROSPECTIVE STUDY; RISK FACTOR; SURVIVAL RATE; TREATMENT OUTCOME;

6-MERCAPTOPURINE; ADOLESCENT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRAZIL; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; INFANT; MALE; METHOTREXATE; NEOPLASM STAGING; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 77951651730     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2009.25.6115     Document Type: Article

References (31)

1. Brandalise SR: Acute lymphoblastic leukemia in children. Presented at the World Congress of the International Society of Hematology, Punta del Este, Uruguay, March 20-24, 2007. Archivos de Medicina Interna 29: S92-S95, 2007 (suppl 1)
2. Schrappe M: Evolution of BFM trials for childhood ALL. Ann Hematol 83:S121-S123, 2004 (suppl 1)
3. Seibel NL, Steinherz PG, Sather HN, et al: Early postinduction intensification therapy improves survival for children and adolescents with high-risk acute lymphoblastic leukemia: A report from the Children's Oncology Group. Blood 111:2548-2555, 2008
4. Pui CH, Evans WE: Treatment of acute lymphoblastic leukemia. N Engl J Med 354:166-178, 2006
5. Hunger SP, Sung L, Howard SC: Treatment strategies and regimens of graduated intensity for childhood acute lymphoblastic leukemia in low-income countries: A proposal. Pediatr Blood Cancer 52:559-565, 2009
6. Pui CH, Robison LL, Look AT: Acute lymphoblastic leukaemia. Lancet 371:1030-1043, 2008 (Pubitemid 351389536)
7. Hunger SP, Winick NJ, Sather HN, et al: Therapy of low-risk subsets of childhood acute lymphoblastic leukemia: When do we say enough? Pediatr Blood Cancer 45:876-880, 2005
8. Berkovitch M, Matsui D, Zipursky A, et al: Hepatotoxicity of 6-mercaptopurine in childhood acute lymphocytic leukemia: Pharmacokinetic characteristics. Med Pediatr Oncol 26:85-89, 1996 (Pubitemid 26010932)
9. Peto J, Eden OB, Lilleyman J, et al: Improvement in treatment for children with acute lymphoblastic leukaemia: The Medical Research Council UKALL trials, 1972-84 - Report to the Council by the Working Party on Leukaemia in Childhood. Lancet 1:408-411, 1986
10. Rapson NT, Cornbleet MA, Chessells JM, et al: Immunosuppression and serious infections in children with acute lymphoblastic leukaemia: A comparison of three chemotherapy regimes. Br J Haematol 45:41-52, 1980 (Pubitemid 10094386)
11. Koizumi S, Fujimoto T, Takeda T, et al: Comparison of intermittent or continuous methotrexate plus 6-mercaptopurine in regimens for standard-risk acute lymphoblastic leukemia in childhood (JCCLSG-S811): The Japanese Children's Cancer and Leukemia Study Group. Cancer 61:1292-1300, 1988 (Pubitemid 18076398)
12. Brandalise SR: Prognostic value of day 8 peripheral blood response for children with acute lymphocytic leukemia, in Zander AR (ed): Gene Technology: Stem Cell and Leukemia Research. Berlin, Germany, Springer-Verlag, 1996, pp 421-428
13. National Cancer Institute: Common Toxicity criteria manual version 2.0 edition. Bethesda, MD, National Cancer Institute, 1999
14. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
15. Peto R, Pike MC, Armitage P, et al: Design and analysis of randomized clinical trials requiring prolonged observation of each patient: II: Analysis and examples. Br J Cancer 35:1-39, 1977 (Pubitemid 8018922)
16. Brandalise SR; Brazilian Cooperative Group: Comparison of intermittent versus continuous methotrexate plus 6-MP in maintenance regimen for standard-risk acute lymphoblastic leukemia in children (GBTLI ALL-99). J Clin Oncol 25:529s, 2007 (abstr 9512)
17. Antillon F, Baez FL, Barr R, et al: AMOR: A proposed cooperative effort to improve outcomes of childhood cancer in Central America. Pediatr Blood Cancer 45:107-110, 2005 (Pubitemid 40993574)
18. Barr RD, Sala A, Wiernikowski J, et al: A formulary for pediatric oncology in developing countries. Pediatr Blood Cancer 44:433-435, 2005 (Pubitemid 40614489)
19. Pedrosa F, Bonilla M, Liu A, et al: Effect of malnutrition at the time of diagnosis on the survival of children treated for cancer in El Salvador and Northern Brazil. J Pediatr Hematol Oncol 22:502-505, 2000 (Pubitemid 33599822)
20. Brandalise SR, Viana MB, Loggetto S, et al: Dexametasone during induction, re-induction and maintenance pulses in low-risk ALL patients (Brazilian Cooperative ALL-93 Protocol- GBTLI ALL-93). J Clin Oncol 23:810s, 2005 (suppl; abstr 8543)
21. Matloub Y, Bostrom BC, Hunger SP, et al: Escalating dose intravenous methotrexate without leucovorin rescue during interim maintenance is superior to oral methotrexate for children with standard risk acute lymphoblastic leukemia (SR-ALL): Children's Oncology Group Study 1991. Blood 112:9-10, 2008 (abstr 9)
22. Brecher ML, Weinberg V, Boyett JM, et al: Intermediate dose methotrexate in childhood acute lymphoblastic leukemia resulting in decreased incidence of testicular relapse. Cancer 58:1024-1028, 1986 (Pubitemid 16046930)
23. Buhrer C, Henze G, Hofmann J, et al: Central nervous system relapse prevention in 1165 standard-risk children with acute lymphoblastic leukemia in five BFM trials. Haematol Blood Transfus 33:500-503, 1990
24. Miller DR, Leikin SL, Albo VC, et al: The prognostic value of testicular biopsy in childhood acute lymphoblastic leukemia: A report from the Childrens' Cancer Study Group. J Clin Oncol 8:57-66, 1990 (Pubitemid 20032447)
25. Pui CH, Boyett JM, Relling MV, et al: Sex differences in prognosis for children with acute lymphoblastic leukemia. J Clin Oncol 17:818-824, 1999 (Pubitemid 29109311)
26. Balis FM, Holcenberg JS, Poplack DG, et al: Pharmacokinetics and pharmacodynamics of oral methotrexate and mercaptopurine in children with lower risk acute lymphoblastic leukemia: A joint Children's Cancer Group and Pediatric Oncology Branch study. Blood 92:3569-3577, 1998 (Pubitemid 28525181)
27. Lonnerholm G, Valsecchi MG, De LP, et al: Pharmacokinetics of high-dose methotrexate in infants treated for acute lymphoblastic leukemia. Pediatr Blood Cancer 52:596-601, 2009
28. Wall AM, Gajjar A, Link A, et al: Individualized methotrexate dosing in children with relapsed acute lymphoblastic leukemia. Leukemia 14:221-225, 2000 (Pubitemid 30095374)
29. Bajel A, George B, Mathews V, et al: Treatment of children with acute lymphoblastic leukemia in India using a BFM protocol. Pediatr Blood Cancer 51:621-625, 2008
30. Spinetta JJ, Masera G, Eden T, et al: Refusal, non-compliance, and abandonment of treatment in children and adolescents with cancer: A report of the SIOP Working Committee on Psychosocial Issues in Pediatric Oncology. Med Pediatr Oncol 38:114-117, 2002 (Pubitemid 34113442)
31. Tang Y, Xu X, Song H, et al: Long-term outcome of childhood acute lymphoblastic leukemia treated in China. Pediatr Blood Cancer 51:380-386, 2008